The National Pharmaceutical Council (NPC) Board of Directors today elected Joshua Ofman, MD, MSHS, Senior Vice President of Global Value, Access & Policy, Amgen, as its 2016-2017 Chairman. Dr. Ofman has served on NPC’s Board since 2012, most recently as Vice Chairman.
“Dr. Ofman’s expertise and passion for bringing breakthrough medicines to patients have shone through during his tenure on NPC’s Board,” said NPC President Dan Leonard. “I’m looking forward to working with Dr. Ofman in his role as our new Board chairman.”
Dr. Ofman has been with Amgen since 2003, where he was previously Vice President, Global Coverage and Reimbursement and Global Health Economics. Prior to Amgen, Dr. Ofman served as Senior Vice President of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies. He was formerly a member of the academic faculty in the Department of Medicine, University of California-Los Angeles (UCLA) School of Medicine, Cedars-Sinai Medical Center. Dr. Ofman received his advanced medical training in gastroenterology from UCLA and his health services research training from the RAND/UCLA/VA program.
“NPC plays an incredibly important role in convening and collaborating with other stakeholders to find solutions to today’s health care policy challenges,” said Dr. Ofman. “Having been part of NPC’s Board for several years, I’ve seen firsthand the importance of their work on issues such as real-world evidence, patient access to medicines, understanding value and encouraging innovation in our health care system.”
The NPC Board elected Jeff Bloss, MD, Senior Vice President, Astellas Medical Affairs, Americas, Astellas Pharma Global Development, Inc., as Vice Chairman. Jeff Stewart, President, U.S. Commercial Operations, AbbVie, and Patrick Magri, Senior Vice President, Hospital & Specialty Business Unit, Merck, who is the Immediate Past Chairman, also will serve on NPC’s Executive Committee.